January 14, 2016
2 min watch
Save

VIDEO: Time to MRD negativity predicted EFS in certain patients with ALL

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

ORLANDO, Fla. — Ryan D. Cassaday, MD, provides an overview of a study presented at the ASH Annual Meeting and Exposition in which he and colleagues determined earlier time to minimal residual disease negativity predicted longer EFS among adults with acute lymphoblastic leukemia treated with the hyper-CVAD regimen.